Kodiak Sciences Inc. (KOD)
NasdaqGM · USD · Healthcare · Biotechnology
$91.32 (+1.92%) as of
Key statistics
- Market cap
- 5.74B
- Forward P/E
- -26.58
- EPS (TTM)
- -4.19
- Dividend yield
- 0.00%
- 52-week range
- 15.83 – 104.00
- Beta
- 2.04
- Profit margin
- 0.00%
- Analyst target
- $121.67
- Volume
- 1.01M
About Kodiak Sciences Inc.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Palo Alto, CA, United States
- Employees
- 141
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.